Abstract
We first synthesized N-pentafluorobenzyl-1-deoxynojirimycin (5F-DNM), one new derivative of 1-deoxynojirimycin (DNM). Effects on human peripheral blood mononuclear cells (PMBC) and secretion of cytokines from human PBMC by 5F-DNM were investigated. It was first found that 5F-DNM remarkably inhibited the secretion of interleukin-4 (IL-4) and had a specific inhibition on the expression of CD4 molecules. 5F-DNM, much less toxic than cyclosporin A, might be used as a new candidate of immunosuppressant for specifically treating Th2-mediated immune diseases.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
1-Deoxynojirimycin / analogs & derivatives*
-
1-Deoxynojirimycin / chemical synthesis
-
1-Deoxynojirimycin / pharmacology*
-
Benzyl Compounds / chemical synthesis
-
Benzyl Compounds / pharmacology*
-
CD4-Positive T-Lymphocytes / cytology
-
CD4-Positive T-Lymphocytes / drug effects*
-
CD4-Positive T-Lymphocytes / metabolism
-
Cyclosporine / therapeutic use
-
Cytokines / metabolism
-
Humans
-
Immunosuppressive Agents / chemical synthesis
-
Immunosuppressive Agents / pharmacology*
-
Interleukin-4 / metabolism
-
Leukocytes, Mononuclear / drug effects
-
Leukocytes, Mononuclear / metabolism
-
Th2 Cells / drug effects
-
Th2 Cells / immunology
-
Th2 Cells / metabolism
Substances
-
Benzyl Compounds
-
Cytokines
-
Immunosuppressive Agents
-
N-pentafluorobenzyl-1-deoxynojirimycin
-
1-Deoxynojirimycin
-
Interleukin-4
-
Cyclosporine